Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and …

2014年5月30日 · Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the nonproprietary name for MK-3475, Merck’s investigational anti-PD-1 …

2015年10月1日 · Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients …

2014年5月14日 · Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy ; Late-breaker presentation of long-term findings of …

2015年9月30日 · Pembrolizumab (MK-3475) is a potent, highly selective, IgG4-κ humanized monoclonal antibody that prevents PD-1 binding with its ligands, PD-L1 and PD-L2. This report …

2012年11月11日 · About PD-1 and MK-3475. Research has shown that PD-1, an immune checkpoint receptor, helps to confer immune resistance for some cancers allowing tumor cells …

Trial P001 is a multicenter, international, open-label, multi-cohort study of MK-3475 in patients with advanced melanoma and carcinoma.

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and …

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 receptor, used in cancer immunotherapy.

2014年5月20日 · MK-3475 is a potent and highly selective humanized monoclonal antibody against PD-1 designed to directly block its interaction with its ligands, PD-L1 and PD-L2, thus …